ZBH Share Price | Zimmer Biomet Holdings, Inc. Stock Analysis & Recommendation

Q: How big is Zimmer Biomet Holdings, Inc.?

Market Cap: As of Jun 18, Zimmer Biomet Holdings, Inc. has a market capitalization of 27,211.66 million, classifying it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Zimmer Biomet reported net sales of 7,698.50 million and a net profit of 914.90 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 12,468.10 million and total assets of 21,365.30 million.

Q: What does Zimmer Biomet Holdings, Inc. do?

Overview:Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing, and marketing orthopedic reconstructive products and related surgical solutions within the Pharmaceuticals & Biotechnology industry, classified as a large-cap company.Financial Snapshot:Most recent Net Sales: 1,909 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 183 Million (Quarterly Results - Mar 2025) Market cap: USD 27,211.66 Million (Large Cap)Key Metrics:P/E: 25.00 Dividend Yield: 73.72% Debt Equity: 0.47 Return on Equity: 8.93% Price to Book: 2.20 Contact Details:Address: 345 E Main St, WARSAW IN: 46580-2746 Tel: 1 574 2676131 Website: http://www.zimmerbiomet.com/

Q: Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Zimmer Biomet Holdings, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing the outlook. The weekly MACD and Bollinger Bands are bearish, while the daily moving averages show a mildly bullish signal. The KST is bullish on a weekly basis but bearish monthly, and Dow Theory indicates a mildly bearish weekly trend alongside a mildly bullish monthly trend. In terms of performance, Zimmer Biomet has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -9.98% versus the S&P 500's 11.41%, and a 5-year return of -32.31% compared to the S&P 500's 88.45%.

Q: Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Agilent Technologies, Inc. has a P/E of 27.42, while GE Healthcare Technologies, Inc. stands out with a much lower P/E of 15.07, indicating that Zimmer Biomet is positioned competitively within its industry.Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -2.32% compared to the index's 16.30%. Over the past five years, the company has seen a decline of 22.03%, while the S&P 500 has gained 109.18%, further emphasizing the challenges the company faces in generating shareholder value.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

592.49 k

Shareholding (Dec 2025)

FII

16.55%

Held by 375 FIIs

DII

20.27%

Held by 87 DIIs

Promoter

0.02%

How big is Zimmer Biomet Holdings, Inc.?

22-Jun-2025

As of Jun 18, Zimmer Biomet Holdings, Inc. has a market capitalization of $27.21 billion, with net sales of $7.70 billion and a net profit of $914.90 million over the latest four quarters.

View full answer

What does Zimmer Biomet Holdings, Inc. do?

22-Jun-2025

Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products and surgical solutions. As of March 2025, it reported net sales of $1.909 billion and a market cap of approximately $27.21 billion.

View full answer

Who are in the management team of Zimmer Biomet Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Zimmer Biomet Holdings, Inc. includes Mr. Larry Glasscock (Independent Non-Executive Chairman), Mr. Bryan Hanson (President and CEO), and several Independent Directors: Mr. Christopher Begley, Ms. Betsy Bernard, Ms. Gail Boudreaux, and Mr. Michael Farrell. They oversee the company's strategic direction and operations.

View full answer

Is Zimmer Biomet Holdings, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Zimmer Biomet Holdings, Inc. shows a neutral trend with mixed indicators, underperforming the S&P 500 year-to-date at -9.98% compared to 11.41%.

View full answer

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, Zimmer Biomet Holdings, Inc. is fairly valued with a P/E ratio of 25, but has underperformed the S&P 500 with a year-to-date return of -2.32% and a five-year decline of 22.03%.

View full answer

Compare Zimmer Biomet Holdings, Inc. with Similar Stocks

Mettler-Toledo International, Inc.West Pharmaceutical Services, Inc.GE Healthcare Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 2.19% and Operating profit at 14.17% over the last 5 years

Negative results in Jun 25

With ROCE of 7.93%, it has a fair valuation with a 1.85 Enterprise value to Capital Employed

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 29,821 Million (Mid Cap)

P/E

29.00

Industry P/E

Dividend Yield

17.30%

Debt Equity

0.55

Return on Equity

7.46%

Price to Book

2.35

Revenue and Profits:

Net Sales:

2,244 Million

(Quarterly Results - Dec 2025)

Net Profit:

138 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.99%

6 Months

-6.84%

1 Year

-4.38%

2 Years

-21.27%

3 Years

-19.31%

4 Years

-19.06%

5 Years

-37.11%

Zimmer Biomet Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.22%

EBIT Growth (5y)

10.25%

EBIT to Interest (avg)

6.38

Debt to EBITDA (avg)

2.71

Net Debt to Equity (avg)

0.47

Sales to Capital Employed (avg)

0.40

Tax Ratio

12.92%

Dividend Payout Ratio

27.05%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

6.76%

ROE (avg)

8.16%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.48

EV to EBIT

26.24

EV to EBITDA

15.27

EV to Capital Employed

1.95

EV to Sales

4.85

PEG Ratio

Dividend Yield

32.65%

ROCE (Latest)

7.42%

ROE (Latest)

8.51%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 151 Schemes (62.83%)

Foreign Institutions

Held by 375 Foreign Institutions (16.55%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 10.90% vs 4.28% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -42.54% vs -42.80% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,243.80",
          "val2": "2,023.20",
          "chgp": "10.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "566.90",
          "val2": "696.90",
          "chgp": "-18.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "71.00",
          "val2": "59.20",
          "chgp": "19.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-133.50",
          "val2": "-67.50",
          "chgp": "-97.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "137.90",
          "val2": "240.00",
          "chgp": "-42.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "126.10%",
          "val2": "214.20%",
          "chgp": "-8.81%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 7.20% vs 3.85% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -22.12% vs -11.70% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,231.50",
          "val2": "7,678.60",
          "chgp": "7.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,416.60",
          "val2": "2,481.30",
          "chgp": "-2.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "284.10",
          "val2": "207.10",
          "chgp": "37.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-271.70",
          "val2": "-326.40",
          "chgp": "16.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "705.00",
          "val2": "905.20",
          "chgp": "-22.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "160.70%",
          "val2": "193.40%",
          "chgp": "-3.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

2,243.80

2,023.20

10.90%

Operating Profit (PBDIT) excl Other Income

566.90

696.90

-18.65%

Interest

71.00

59.20

19.93%

Exceptional Items

-133.50

-67.50

-97.78%

Consolidate Net Profit

137.90

240.00

-42.54%

Operating Profit Margin (Excl OI)

126.10%

214.20%

-8.81%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 10.90% vs 4.28% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -42.54% vs -42.80% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

8,231.50

7,678.60

7.20%

Operating Profit (PBDIT) excl Other Income

2,416.60

2,481.30

-2.61%

Interest

284.10

207.10

37.18%

Exceptional Items

-271.70

-326.40

16.76%

Consolidate Net Profit

705.00

905.20

-22.12%

Operating Profit Margin (Excl OI)

160.70%

193.40%

-3.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 7.20% vs 3.85% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -22.12% vs -11.70% in Dec 2024

All Annual Results

Company CV

About Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc.

Pharmaceuticals & Biotechnology

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

Company Coordinates

Company Details

345 E Main St , WARSAW IN : 46580-2746

Tel: 1 574 2676131

http://www.zimmerbiomet.com/

Registrar Details